Anagenics Limited (AN1.AX)
- Previous Close
0.0100 - Open
0.0090 - Bid 0.0090 x --
- Ask 0.0100 x --
- Day's Range
0.0090 - 0.0090 - 52 Week Range
0.0090 - 0.0280 - Volume
5,389 - Avg. Volume
425,018 - Market Cap (intraday)
4.152M - Beta (5Y Monthly) -1.02
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Feb 26, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Anagenics Limited operates as a health and beauty tech company in Australia, New Zealand, and internationally. It develops and sells FGF5 inhibitor formulations; over-the-counter (OTC), cosmetic antiaging, and longevity targeting products; and imports and distributes international and local skin care and wellbeing products under the Thalgo, Hydro Peptide, Comfort Zone, Priori, and Inika Organic brand names. The company also develops, manufactures, and markets beauty and wellness brands comprising Uspa and evolis. It offers its products through various channels, including clinics, retail stores, wholesale pharmacy and spa/salons, online ecommerce, and cross border export markets. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.
anagenics.com--
Full Time Employees
June 30
Fiscal Year Ends
Sector
Industry
Related News
Performance Overview: AN1.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AN1.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AN1.AX
Valuation Measures
Market Cap
4.15M
Enterprise Value
3.67M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.30
Price/Book (mrq)
0.58
Enterprise Value/Revenue
0.36
Enterprise Value/EBITDA
-1.76
Financial Highlights
Profitability and Income Statement
Profit Margin
-30.99%
Return on Assets (ttm)
-12.95%
Return on Equity (ttm)
-35.76%
Revenue (ttm)
10.2M
Net Income Avi to Common (ttm)
-2.58M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
1.35M
Total Debt/Equity (mrq)
12.17%
Levered Free Cash Flow (ttm)
-805.83k
Company Insights: AN1.AX
AN1.AX does not have Company Insights